Two‐year outcomes of the ARTISAN‐SNM study for the treatment of urinary urgency incontinence using the Axonics rechargeable sacral neuromodulation system

Sacral neuromodulation (SNM) is a guideline‐recommended treatment with proven therapeutic benefit for urinary urgency incontinence (UUI) patients. The Axonics® System is the first Food and Drug Administration‐approved rechargeable SNM system and is designed to deliver therapy for a minimum of 15 years. The ARTISAN‐SNM study was designed to evaluate UUI participants treated with the Axonics System. Two‐year follow‐up results are presented.

[1]  B. Blok,et al.  One‐year outcomes of the ARTISAN‐SNM study with the Axonics System for the treatment of urinary urgency incontinence , 2020, Neurourology and urodynamics.

[2]  K. Matzel,et al.  New Technologies and Applications in Sacral Neuromodulation: An Update , 2019, Advances in Therapy.

[3]  L. Souter,et al.  Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment 2019. , 2019, The Journal of urology.

[4]  U. Lee,et al.  Outcomes in a contemporary cohort undergoing sacral neuromodulation using optimized lead placement technique , 2019, Neurourology and urodynamics.

[5]  J. Hippisley-Cox,et al.  Anticholinergic Drug Exposure and the Risk of Dementia , 2019, JAMA internal medicine.

[6]  T. Kessler,et al.  Sacral neuromodulation using the standardized tined lead implantation technique with a curved vs a straight stylet: 2‐year clinical outcomes and sensory responses to lead stimulation , 2019, BJU international.

[7]  K. Ashkan,et al.  Fixed‐Life or Rechargeable Battery for Deep Brain Stimulation: Which Do Patients Prefer? , 2018, Neuromodulation : journal of the International Neuromodulation Society.

[8]  B. Blok,et al.  Treatment of Urinary Urgency Incontinence Using a Rechargeable SNM System: 6-month Results of the ARTISAN-SNM Study. , 2019, The Journal of urology.

[9]  D. Myers,et al.  Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial. , 2018, European urology.

[10]  K. Matzel,et al.  International continence society best practice statement for use of sacral neuromodulation , 2018, Neurourology and urodynamics.

[11]  D. Elterman,et al.  The novel Axonics® rechargeable sacral neuromodulation system: Procedural and technical impressions from an initial North American experience , 2018, Neurourology and urodynamics.

[12]  C. Comiter,et al.  Five‐Year Followup Results of a Prospective, Multicenter Study of Patients with Overactive Bladder Treated with Sacral Neuromodulation , 2018, The Journal of urology.

[13]  K. Matzel,et al.  Sacral Neuromodulation: Standardized Electrode Placement Technique , 2017, Neuromodulation : journal of the International Neuromodulation Society.

[14]  R. Dmochowski,et al.  Cost profiles and budget impact of rechargeable versus non‐rechargeable sacral neuromodulation devices in the treatment of overactive bladder syndrome , 2017, Neurourology and urodynamics.

[15]  M. Hudson,et al.  Clinical correlates of faecal incontinence in systemic sclerosis: identifying therapeutic avenues , 2016, Rheumatology.

[16]  C. Comiter,et al.  Three-year Follow-up Results of a Prospective, Multicenter Study in Overactive Bladder Subjects Treated With Sacral Neuromodulation. , 2016, Urology.

[17]  C. Comiter,et al.  Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder , 2016, Neurourology and urodynamics.

[18]  Sean Nicholson,et al.  Global prevalence and economic burden of urgency urinary incontinence: a systematic review. , 2014, European urology.

[19]  T. Griebling.  WORLDWIDE PREVALENCE ESTIMATES OF LOWER URINARY TRACT SYMPTOMS, OVERACTIVE BLADDER, URINARY INCONTINENCE, AND BLADDER OUTLET OBSTRUCTION , 2011, BJU international.

[20]  M. Elhilali,et al.  Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. , 2007, The Journal of urology.

[21]  L. Matza,et al.  Determining the importance of change in the overactive bladder questionnaire. , 2006, The Journal of urology.